Low-risk metastatic gestational trophoblastic disease is highly curable with single-agent chemotherapy. Careful monitoring of the response to therapy is essential so that one can alter treatment when signs of drug resistance occur. Because some low-risk patients require complex chemotherapy and/or surgery before achieving remission, therapy should be directed by experienced clinicians at facilities where appropriate ancillary services are available.